Myricx Bio has secured USD GBP 90 million (~USD 115.3 million) in a Series A funding round led jointly by Novo Holdings and Abingworth, with participation from Eli Lilly, Cancer Research Horizons, British Patient Capital, Sofinnova Partners, and Brandon Capital.
The funds are planned to be directed toward expanding Myricx’s proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and progressing its pipeline of NMTi-ADCs to the proof-of-concept stage.
UK-based Myricx Bio specializes in discovering and developing a novel class of selective cytotoxic payloads for antibody-drug conjugates (ADCs). The company's proprietary ADCs are claimed to have shown preclinical efficacy and safety across various solid tumor-associated antigens and specific cancer cell types. Myricx Bio is currently focused on developing and refining its NMTi ADC platform to progress its operations into the clinical stage.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.